News
SNY
47.99
-0.31%
-0.15
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
Benzinga · 13h ago
UPDATE 3-AbbVie, several other pharma companies near MFN deal with Trump, sources say
Reuters · 1d ago
Salesforce’s Agentforce Life Sciences Gains Traction with Another Healthcare Provider Onboard
TipRanks · 1d ago
TD Cowen Reaffirms Their Hold Rating on Sanofi (SNY)
TipRanks · 1d ago
More pharmas expected to sign drug pricing deals with Trump on Friday - report
Seeking Alpha · 1d ago
BUZZ-Cytokinetics rises after winning China approval for heart disease drug
Reuters · 1d ago
China Approves Cytokinetics' MYQORZO for Obstructive Hypertrophic Cardiomyopathy
Reuters · 1d ago
Sanofi Receives EMA Orphan Designation For Efdoralprin Alfa
NASDAQ · 1d ago
Sanofi SA releases Q4 2025 Aide Memoire for investor guidance
Reuters · 1d ago
Sanofi Secures EU Orphan Designation For Efdoralprin Alfa In Alpha-1 Antitrypsin Deficiency Related Emphysema
Benzinga · 1d ago
SANOFI - FDA GRANTS FAST TRACK AND ORPHAN DESIGNATION TO EFDORALPRIN ALFA
Reuters · 1d ago
Inhibrx Biosciences Advances INBRX-106 Phase 2/3 Trial for Head and Neck Cancer
Reuters · 2d ago
Pfizer leads COVID-19 vaccine peers lower after revamped guidance
Seeking Alpha · 2d ago
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
NASDAQ · 2d ago
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?
NASDAQ · 2d ago
Sanofi in up to $1B deal with South Korean biotech for Alzheimer's candidate
Seeking Alpha · 2d ago
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi
Reuters · 3d ago
Cogent Biosciences: Time For A Pause
Seeking Alpha · 3d ago
ADEL: GRANTS EXCLUSIVE WORLDWIDE RIGHTS FOR ACETYLATED TAU-TARGETING ANTIBODY 'ADEL-Y01' TO SANOFI
Reuters · 3d ago
ADEL: DEAL INCLUDES $80 MLN UPFRONT PAYMENT, WITH TOTAL POTENTIAL VALUE UP TO $1.04 BLN PLUS ROYALTIES
Reuters · 3d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.